Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.
about
Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculationTrial WatchTrial Watch-Immunostimulation with cytokines in cancer therapyTrial watch: Immunostimulatory cytokines in cancer therapy.20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose mattersTNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculatureTrial Watch: Immunostimulatory cytokines.The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.Oxaliplatin and Infliximab Combination Synergizes in Inducing Colon Cancer Regression.Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?Current position of TNF-α in melanomagenesis.Plastic Surgery in the Multimodal Treatment Concept of Soft Tissue Sarcoma: Influence of Radiation, Chemotherapy, and Isolated Limb Perfusion on Plastic Surgery Techniques.Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity.Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapyIsolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
P2860
Q21245599-558930CF-6825-4FC1-880F-68BDF9663FDEQ24618653-7140D990-0F85-48CC-96E6-FF5395F4F671Q28078725-E16C7C45-3A42-4EAE-AE1A-801C3B1DBAB2Q33880165-3A443A12-1171-4841-9511-79A1CD9E6BCDQ34006197-6D7B199D-7500-4F15-9BE9-12B75A4032D7Q35690539-44C24297-A934-4865-AE86-CE0347C1B2F7Q36057492-97D5AA2F-DDC1-4150-928C-570EF5F2AE8BQ36102807-F407D280-5D19-44FE-A6C1-7E37B608F6DBQ37656158-D6A7DC3D-D5A5-4C66-B9E9-BDD5FBAE0E44Q38176854-9EF86D43-D612-4F21-8927-BE3A6B51A08EQ38567932-BD901FD9-2300-45BA-A500-03774B306AB4Q38663542-BC176C56-689A-4771-AA0C-6D4D4B7E3898Q38966445-4B270332-3FBB-48C8-8862-37958E68ED2EQ39026497-410204E8-4995-4570-8A47-AFDE98D40CC9Q44862870-2B3E11A7-F6E4-4C85-BEED-AD6D634AD06EQ47985650-DA4381EE-26AC-4BB3-934D-581E2371A75DQ56892924-78C5ACE4-853A-4DB3-A00F-D0544AE848CFQ57911958-FC1ABC39-E519-4206-B0B4-B6EC796B9480
P2860
Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Long-term outcome of isolated ...... elanoma in-transit metastases.
@ast
Long-term outcome of isolated ...... elanoma in-transit metastases.
@en
type
label
Long-term outcome of isolated ...... elanoma in-transit metastases.
@ast
Long-term outcome of isolated ...... elanoma in-transit metastases.
@en
prefLabel
Long-term outcome of isolated ...... elanoma in-transit metastases.
@ast
Long-term outcome of isolated ...... elanoma in-transit metastases.
@en
P2093
P2860
P356
P1476
Long-term outcome of isolated ...... melanoma in-transit metastases
@en
P2093
A M M Eggermont
A N van Geel
J H W de Wilt
J P Deroose
P2860
P304
P356
10.1002/BJS.7621
P407
P577
2011-07-08T00:00:00Z